Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia

Maju Mathew Koola, Robert W. Buchanan, Anilkumar Pillai, Katherine J. Aitchison, Daniel R. Weinberger, Scott T. Aaronson, Faith B. Dickerson

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified three drug mechanisms of particular interest: dopaminergic, cholinergic, and glutamatergic. As a group, while people with schizophrenia have moderate cognitive impairment, it is the best predictor of long-term outcome. Unfortunately, there are no approved medications for cognitive impairment in this population. Hence, the development of new pharmacological approaches is critical for reducing illness-related disability. The combination of an acetylcholinesterase inhibitor (AChEI) and memantine is more effective than either medication alone to improve cognition in Alzheimer's dementia. Galantamine is not only an AChEI, but also a positive allosteric modulator of the α4β2 and α7 nicotinic receptors. Hypofunction of N-methyl-d-aspartate (NMDA) receptors has been implicated in the pathophysiology of cognitive symptoms in schizophrenia and hence memantine may positively impact cognition. Memantine decreases the tonic NMDA current and galantamine enhances the action potential mediated by a postsynaptic NMDA current. This results in an increased signal transmission; therefore, a greater signal-to-noise ratio occurs with the combination than memantine alone. Galantamine improves the α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate (AMPA)-mediated signaling which could be neuroprotective and may improve memory coding. The combination of galantamine and memantine may be particularly effective in schizophrenia in order to increase the selective cognition enhancement produced by either medication alone. In the future, multitarget-directed ligands may play a role in the treatment of complex diseases like schizophrenia.

Original languageEnglish (US)
Pages (from-to)84-89
Number of pages6
JournalSchizophrenia Research
Volume157
Issue number1-3
DOIs
StatePublished - Aug 2014

Fingerprint

Galantamine
Memantine
Cognition
Schizophrenia
Cholinesterase Inhibitors
Aspartic Acid
Research
Neurobehavioral Manifestations
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Propionates
Nicotinic Receptors
Signal-To-Noise Ratio
Critical Illness
Pharmaceutical Preparations
Cholinergic Agents
Action Potentials
Alzheimer Disease
Pharmacology
Ligands

Keywords

  • Cognitive impairments
  • Galantamine
  • Memantine
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Koola, M. M., Buchanan, R. W., Pillai, A., Aitchison, K. J., Weinberger, D. R., Aaronson, S. T., & Dickerson, F. B. (2014). Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophrenia Research, 157(1-3), 84-89. https://doi.org/10.1016/j.schres.2014.04.037

Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. / Koola, Maju Mathew; Buchanan, Robert W.; Pillai, Anilkumar; Aitchison, Katherine J.; Weinberger, Daniel R.; Aaronson, Scott T.; Dickerson, Faith B.

In: Schizophrenia Research, Vol. 157, No. 1-3, 08.2014, p. 84-89.

Research output: Contribution to journalReview article

Koola, MM, Buchanan, RW, Pillai, A, Aitchison, KJ, Weinberger, DR, Aaronson, ST & Dickerson, FB 2014, 'Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia', Schizophrenia Research, vol. 157, no. 1-3, pp. 84-89. https://doi.org/10.1016/j.schres.2014.04.037
Koola, Maju Mathew ; Buchanan, Robert W. ; Pillai, Anilkumar ; Aitchison, Katherine J. ; Weinberger, Daniel R. ; Aaronson, Scott T. ; Dickerson, Faith B. / Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. In: Schizophrenia Research. 2014 ; Vol. 157, No. 1-3. pp. 84-89.
@article{1c2e3001b797487ca441f982b1b7ab78,
title = "Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia",
abstract = "The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified three drug mechanisms of particular interest: dopaminergic, cholinergic, and glutamatergic. As a group, while people with schizophrenia have moderate cognitive impairment, it is the best predictor of long-term outcome. Unfortunately, there are no approved medications for cognitive impairment in this population. Hence, the development of new pharmacological approaches is critical for reducing illness-related disability. The combination of an acetylcholinesterase inhibitor (AChEI) and memantine is more effective than either medication alone to improve cognition in Alzheimer's dementia. Galantamine is not only an AChEI, but also a positive allosteric modulator of the α4β2 and α7 nicotinic receptors. Hypofunction of N-methyl-d-aspartate (NMDA) receptors has been implicated in the pathophysiology of cognitive symptoms in schizophrenia and hence memantine may positively impact cognition. Memantine decreases the tonic NMDA current and galantamine enhances the action potential mediated by a postsynaptic NMDA current. This results in an increased signal transmission; therefore, a greater signal-to-noise ratio occurs with the combination than memantine alone. Galantamine improves the α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate (AMPA)-mediated signaling which could be neuroprotective and may improve memory coding. The combination of galantamine and memantine may be particularly effective in schizophrenia in order to increase the selective cognition enhancement produced by either medication alone. In the future, multitarget-directed ligands may play a role in the treatment of complex diseases like schizophrenia.",
keywords = "Cognitive impairments, Galantamine, Memantine, Schizophrenia",
author = "Koola, {Maju Mathew} and Buchanan, {Robert W.} and Anilkumar Pillai and Aitchison, {Katherine J.} and Weinberger, {Daniel R.} and Aaronson, {Scott T.} and Dickerson, {Faith B.}",
year = "2014",
month = "8",
doi = "10.1016/j.schres.2014.04.037",
language = "English (US)",
volume = "157",
pages = "84--89",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia

AU - Koola, Maju Mathew

AU - Buchanan, Robert W.

AU - Pillai, Anilkumar

AU - Aitchison, Katherine J.

AU - Weinberger, Daniel R.

AU - Aaronson, Scott T.

AU - Dickerson, Faith B.

PY - 2014/8

Y1 - 2014/8

N2 - The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified three drug mechanisms of particular interest: dopaminergic, cholinergic, and glutamatergic. As a group, while people with schizophrenia have moderate cognitive impairment, it is the best predictor of long-term outcome. Unfortunately, there are no approved medications for cognitive impairment in this population. Hence, the development of new pharmacological approaches is critical for reducing illness-related disability. The combination of an acetylcholinesterase inhibitor (AChEI) and memantine is more effective than either medication alone to improve cognition in Alzheimer's dementia. Galantamine is not only an AChEI, but also a positive allosteric modulator of the α4β2 and α7 nicotinic receptors. Hypofunction of N-methyl-d-aspartate (NMDA) receptors has been implicated in the pathophysiology of cognitive symptoms in schizophrenia and hence memantine may positively impact cognition. Memantine decreases the tonic NMDA current and galantamine enhances the action potential mediated by a postsynaptic NMDA current. This results in an increased signal transmission; therefore, a greater signal-to-noise ratio occurs with the combination than memantine alone. Galantamine improves the α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate (AMPA)-mediated signaling which could be neuroprotective and may improve memory coding. The combination of galantamine and memantine may be particularly effective in schizophrenia in order to increase the selective cognition enhancement produced by either medication alone. In the future, multitarget-directed ligands may play a role in the treatment of complex diseases like schizophrenia.

AB - The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified three drug mechanisms of particular interest: dopaminergic, cholinergic, and glutamatergic. As a group, while people with schizophrenia have moderate cognitive impairment, it is the best predictor of long-term outcome. Unfortunately, there are no approved medications for cognitive impairment in this population. Hence, the development of new pharmacological approaches is critical for reducing illness-related disability. The combination of an acetylcholinesterase inhibitor (AChEI) and memantine is more effective than either medication alone to improve cognition in Alzheimer's dementia. Galantamine is not only an AChEI, but also a positive allosteric modulator of the α4β2 and α7 nicotinic receptors. Hypofunction of N-methyl-d-aspartate (NMDA) receptors has been implicated in the pathophysiology of cognitive symptoms in schizophrenia and hence memantine may positively impact cognition. Memantine decreases the tonic NMDA current and galantamine enhances the action potential mediated by a postsynaptic NMDA current. This results in an increased signal transmission; therefore, a greater signal-to-noise ratio occurs with the combination than memantine alone. Galantamine improves the α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate (AMPA)-mediated signaling which could be neuroprotective and may improve memory coding. The combination of galantamine and memantine may be particularly effective in schizophrenia in order to increase the selective cognition enhancement produced by either medication alone. In the future, multitarget-directed ligands may play a role in the treatment of complex diseases like schizophrenia.

KW - Cognitive impairments

KW - Galantamine

KW - Memantine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84904107880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904107880&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2014.04.037

DO - 10.1016/j.schres.2014.04.037

M3 - Review article

C2 - 24878431

AN - SCOPUS:84904107880

VL - 157

SP - 84

EP - 89

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -